Changing the future of Oncology.
Events
Sutro Biopharma Named Best New Drug Developer at the 7th Annual World ADC
SOUTH SAN FRANCISCO, Calif., Sept. 21, 2020 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company today announced that it has been recognized as Best New Drug Developer at the World ADC Digital Awards, held...
Sutro Biopharma Presents at World ADC 2020 – PowerPoint Presentation
To download the World ADC presentation by Arturo Molina, MD, MS, Chief Medical Officer, CLICK HERE To download the World ADC presentation by Trevor Hallam, Ph.D., Chief Scientific Officer, CLICK HERE To download the World ADC presentation by Shabbir Anik, Ph.D.,...
Cantor Fitzgerald Virtual Heathcare Conference 2020 – PowerPoint Presentation
To download the presentation, Click Here
Sutro Biopharma Presents Promising STRO-002 Interim Phase 1 Clinical Data in Ovarian Cancer at the 2020 IGCS Annual Global Meeting
Updated Data Further Demonstrate Promising Efficacy and Safety Profile in a Heavily Pretreated Patient Population Not Selected Based on Receptor Expression Conference Call Today Scheduled for 5:30 p.m. Eastern Time SOUTH SAN FRANCISCO, Calif., Sept. 9, 2020 – Sutro...
Sutro Biopharma to Present at Two Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 3, 2020 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology...
Sutro Biopharma Announces Promising STRO-002 Interim Phase 1 Clinical Data in Ovarian Cancer and Presentation at the 2020 IGCS Annual Global Meeting
Ongoing Data Further Demonstrate Promising Efficacy and Safety Profile in a Heavily Pretreated Patient Population Not Selected Based on Receptor Expression Conference Call Scheduled for Sept 9, 2020 at 5:30 p.m. Eastern Time SOUTH SAN FRANCISCO, Calif., Sept. 2, 2020...
Sutro Biopharma to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
SOUTH SAN FRANCISCO, Calif., August 10, 2020 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology...
Bristol Myers Squibb Investor Series
June 25, 2020 at 11:30am ET WEBCAST View This Presentation June 22, 2020 at 11:30am ET WEBCAST View This Presentation
M1231: A First In-Class Bispecific ADC Targeting EGFR and MUC1 Presented by EMD Serono at American Association for Cancer Research (AACR) Virtual Meeting II on June 24, 2020 – Presentation
AACR requires pre-registration to access this presentation. Oral Presentation & Discussion, timestamp 1:43:36, Only Available to Registrants , CLICK HERE
Sutro Biopharma Presents New Preclinical Data at 2020 AACR Virtual Annual Meeting II Suggesting Synergy between its STRO-002 Antibody-Drug Conjugate and Immune Checkpoint Inhibitors Resulting in Tumor Regression and Adaptive Anti-Tumor Immunity
Additionally, Sutro’s partner Merck KGaA, Darmstadt, Germany, will be unveiling preclinical data from the collaboration’s pre-Development Candidate, a first-in-class bispecific antibody-drug conjugate targeting EGFR and MUC1 SOUTH SAN FRANCISCO, Calif., June 22, 2020...